PMID- 38183334
OWN - NLM
STAT- MEDLINE
DCOM- 20240313
LR  - 20240313
IS  - 2410-8650 (Electronic)
IS  - 1607-551X (Linking)
VI  - 40
IP  - 3
DP  - 2024 Mar
TI  - Recent advances in the treatment of type 2 diabetes mellitus using new drug 
      therapies.
PG  - 212-220
LID - 10.1002/kjm2.12800 [doi]
AB  - Several recent advances provide multiple health benefits to individuals with type 
      2 diabetes mellitus (T2DM). Pharmacological therapy is governed by 
      person-centered factors, including comorbidities and treatment goals. Adults with 
      T2DM who have an established/high risk of atherosclerotic cardiovascular disease, 
      heart failure, and/or chronic kidney disease, require a treatment regimen that 
      includes agents that are proven to reduce cardiorenal risk. Weight management 
      plays a key role in reducing glucose for patients with T2DM. A glucose-reduction 
      treatment regimen must consider weight management. Sodium glucose co-transporter 
      2 (SGLT2) inhibitors reduce the risk of heart failure, cardiovascular and renal 
      events. Glucagon-like peptide-1 (GLP-1) receptor agonists allow better control of 
      glycemia, promote weight loss and reduce the risk of cardiovascular events. Newer 
      Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 dual agonist, which 
      activate GIP and GLP-1 receptors improve glycemic control and promote greater 
      weight loss than GLP-1 receptor agonists. Several novel drugs are in the clinical 
      development phase. This review pertains to recent advances in pharmacological 
      management of type 2 diabetes.
CI  - (c) 2024 The Authors. The Kaohsiung Journal of Medical Sciences published by John 
      Wiley & Sons Australia, Ltd on behalf of Kaohsiung Medical University.
FAU - Chong, Keong
AU  - Chong K
AUID- ORCID: 0000-0002-0794-2899
AD  - Department of Internal Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan.
AD  - Department of Nursing, Yuanpei University of Medical Technology, Hsinchu, Taiwan.
FAU - Chang, Jack Keng-Jui
AU  - Chang JK
AD  - Biological Programs for Younger Scholar, Academia Sinica, Taipei, Taiwan.
FAU - Chuang, Lee-Ming
AU  - Chuang LM
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei, 
      Taiwan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240106
PL  - China (Republic : 1949- )
TA  - Kaohsiung J Med Sci
JT  - The Kaohsiung journal of medical sciences
JID - 100960562
RN  - 0 (Hypoglycemic Agents)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy/chemically induced
MH  - Hypoglycemic Agents/therapeutic use
MH  - Glucagon-Like Peptide 1/therapeutic use/pharmacology
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Glucose
MH  - Weight Loss
MH  - *Heart Failure
OTO - NOTNLM
OT  - glucagon-like peptide-1 (GLP-1) receptor agonists
OT  - insulin icodec
OT  - retatrutide
OT  - sodium glucose co-transporters 2 (SGLT2) inhibitors
OT  - tirzepatide
EDAT- 2024/01/07 06:43
MHDA- 2024/03/13 06:47
CRDT- 2024/01/06 09:54
PHST- 2023/12/11 00:00 [revised]
PHST- 2023/11/24 00:00 [received]
PHST- 2023/12/12 00:00 [accepted]
PHST- 2024/03/13 06:47 [medline]
PHST- 2024/01/07 06:43 [pubmed]
PHST- 2024/01/06 09:54 [entrez]
AID - 10.1002/kjm2.12800 [doi]
PST - ppublish
SO  - Kaohsiung J Med Sci. 2024 Mar;40(3):212-220. doi: 10.1002/kjm2.12800. Epub 2024 
      Jan 6.